Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings    ZBH

ZIMMER BIOMET HOLDINGS

(ZBH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/17/2020 11/18/2020 11/19/2020 11/20/2020 11/23/2020 Date
150.15(c) 148.19(c) 146.53(c) 145.94(c) 146.24(c) Last
1 363 141 1 531 698 1 777 335 1 462 558 659 118 Volume
-0.05% -1.31% -1.12% -0.40% +0.21% Change
More quotes
Financials (USD)
Sales 2020 7 059 M - -
Net income 2020 -167 M - -
Net Debt 2020 6 769 M - -
P/E ratio 2020 -179x
Yield 2020 0,66%
Sales 2021 8 104 M - -
Net income 2021 1 114 M - -
Net Debt 2021 5 325 M - -
P/E ratio 2021 27,7x
Yield 2021 0,69%
Capitalization 30 250 M 30 250 M -
EV / Sales 2020 5,24x
EV / Sales 2021 4,39x
Nbr of Employees 19 900
Free-Float 66,5%
More Financials
Company
Zimmer Biomet Holdings specializes in designing, manufacturing, and selling orthopedic and dental reconstruction implants, spinal implants, and traumatology products. Net sales break down by family of products as follows: - reconstruction implants (59.4%): knees replacement (59.2% of net sales), hips replacement (40.8%) ; - surgical products and traumatology equipment (22.5%); - spinal implants (9.4%); - dental... 
More about the company
Notations Surperformance© of Zimmer Biomet Holdings
Trading Rating : Investor Rating :
More Ratings
All news about ZIMMER BIOMET HOLDINGS
11/18ZIMMER BIOMET : to Present at 2020 Evercore ISI HealthCONx Conference and Piper ..
AQ
11/17ZIMMER BIOMET : to Present at 2020 Evercore ISI HealthCONx Conference and Piper ..
PR
11/09ZIMMER BIOMET : Announces Third Quarter 2020 Financial Results
AQ
11/06ZIMMER BIOMET : Management's Discussion and Analysis of Financial Condition and ..
AQ
11/06ZIMMER : 3Q Earnings Snapshot
AQ
11/06ZIMMER BIOMET HOLDINGS, INC. : Results of Operations and Financial Condition (fo..
AQ
11/06ACELRX PHARMACEUTICALS : Reports Third Quarter 2020 Financial Results
AQ
11/06ZIMMER BIOMET : Announces Preliminary Results from mymobility Clinical Study at ..
AQ
11/06ZIMMER BIOMET : Announces Third Quarter 2020 Financial Results
PR
11/05BACTIGUARD : Interim report for Q3 2020
AQ
11/03ZIMMER BIOMET HOLDINGS : quaterly earnings release
11/03ZIMMER BIOMET : to Present at Stifel Virtual Healthcare Conference
AQ
11/02ZIMMER BIOMET : to Present at Stifel Virtual Healthcare Conference
PR
10/29ZIMMER BIOMET : to Present at the SVB Leerink CybeRx Series Conference
PR
10/21ZIMMER BIOMET : Empowers Joint Surgery Candidates Who Have Delayed Procedures, '..
AQ
More news
News in other languages on ZIMMER BIOMET HOLDINGS
11/03ZIMMER BIOMET HOLDINGS : Veröffentlichung des Quartalsergebnisses
11/03ZIMMER BIOMET HOLDINGS : publication des résultats trimestriels
07/30ZIMMER BIOMET HOLDINGS : publication des résultats semestriels
07/30ZIMMER BIOMET HOLDINGS : Veröffentlichung des Halbjahresergebnisses
07/15Medicrea n’échappe pas au destin américain des medtech françaises
More news
Analyst Recommendations on ZIMMER BIOMET HOLDINGS
More recommendations
Chart ZIMMER BIOMET HOLDINGS
Duration : Period :
Zimmer Biomet Holdings Technical Analysis Chart | ZBH | US98956P1021 | MarketScreener
Technical analysis trends ZIMMER BIOMET HOLDINGS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 157,07 $
Last Close Price 146,24 $
Spread / Highest target 19,7%
Spread / Average Target 7,41%
Spread / Lowest Target -27,5%
EPS Revisions
Managers
NameTitle
Bryan C. Hanson President, Chief Executive Officer & Director
Larry C. Glasscock Non-Executive Chairman
Kenneth R. Tripp Senior VP-Global Operations & Logistics
Suketu P. Upadhyay Executive VP, Chief Financial & Accounting Officer
David J. Kunz VP-Global Quality, Clinical & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
ZIMMER BIOMET HOLDINGS-2.30%30 250
ABBOTT LABORATORIES25.80%193 666
MEDTRONIC PLC-2.19%149 189
BECTON, DICKINSON AND COMPANY-15.99%66 229
HOYA CORPORATION20.05%44 928
BAXTER INTERNATIONAL INC.-9.39%38 705